LYON, France and CAMBRIDGE, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen ,
Second European source of donor red blood cells secured in preparation for expanded production of red blood cell-based therapeutics LYON, France and CAMBRIDGE, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
Greater than 50% enrollment achieved in ongoing Phase 3 trial of eryaspase in pancreatic cancer Trial in Progress Poster selected for inclusion in Poster Walk LYON, France and CAMBRIDGE, Mass. , Jan. 24, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors LYON, France and CAMBRIDGE, Mass. , Nov. 25, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq and Euronext : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
LYON, France and Cambridge, Mass. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen , Chief
Conference call and webcast on Friday, November 8 at 2:30 pm CET/8:30 am ET TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer: positive safety review by independent data monitoring committee opened for patient enrollment in the United States first U.S.
LYON, France , Nov. 05, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter
